| AzaSite (1% azithromycin ophthalmic solution) / Sun Pharma, Akorn, Nicox |
NCT00564447: Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers |
|
|
| Completed | 4 | 48 | US | Azithromycin, AzaSite, Moxifloxacin, Vigamox | Merck Sharp & Dohme LLC | Bacterial Infections, Eye Infections | 12/07 | | | |
NCT00575380: Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery |
|
|
| Completed | 4 | 116 | US | AzaSite Eye Drops, AzaSite (azithromycin ophthalmic solution), Vigamox Eye Drops, Vigamox(moxifloxacin hydrochloride ophthalmic solution) | Merck Sharp & Dohme LLC | Bacterial Infections, Eye Infections, Cataract Extraction | 06/08 | | | |
NCT00629590: Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis |
|
|
| Completed | 4 | 20 | US | AzaSite®, AzaSite | Merck Sharp & Dohme LLC | Blepharitis | 07/08 | | | |
NCT00629941: Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis |
|
|
| Completed | 4 | 25 | US | AzaSite® | Merck Sharp & Dohme LLC | Blepharitis | 08/08 | | | |
NCT00629980: Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis |
|
|
| Completed | 4 | 60 | US | AzaSite® | Merck Sharp & Dohme LLC | Blepharitis | 09/08 | | | |
NCT00575367: Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers |
|
|
| Completed | 4 | 37 | US | AzaSite (azithromycin ophthalmic solution), Vigamox (moxifloxacin hydrochloride ophthalmic solution) | Merck Sharp & Dohme LLC | Bacterial Infections, Eye Infections | 10/08 | | | |
NCT00656539: Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis |
|
|
| Completed | 4 | 20 | US | AzaSite® | Merck Sharp & Dohme LLC | Blepharitis | 11/08 | | | |
NCT00803452: Lipids of the Human Tear Film and Their Effect on Tear Stability |
|
|
| Completed | 4 | 31 | US | doxycycline, Minocycline, azithromycin, Azasite | University of Louisville | Blepharitis | 12/10 | 12/10 | | |
